全球首款!科济药业 Claudin18.2 CAR-T 疗法提交上市申请

医麦客
Yesterday

2025 年 6 月 26 日医麦客新闻 eMedClub News6 月 25 日,科济药业宣布,其自体Claudin18.2 CAR-T 细胞产品舒瑞基奥仑赛注射液(CT041)的新药上市申请(NDA)已正式提交至中国国家药品监督管理局(NMPA)药品审评中心(CDE),拟用于治疗Claudin18.2 表达阳性、至少二线治疗失败的晚期胃/食管胃结合部腺癌(G/GEJA)患者。官方新闻稿指出,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10